---
id: trial_002
type: clinical_trial
topic: NASH/MASH treatment
disease: Nonalcoholic steatohepatitis
molecule: Resmetirom
phase: Phase 3
status: Completed
---

Trial: MAESTRO-NASH - Resmetirom for NASH with Liver Fibrosis

Sponsor: Madrigal Pharmaceuticals
Enrollment: 966 patients
Duration: 52 weeks
Population: Adults with biopsy-confirmed NASH and stage F1B-F3 fibrosis

Primary Endpoints: 
1. NASH resolution without worsening fibrosis
2. â‰¥1 stage fibrosis improvement without NASH worsening

Results (80mg dose):
- NASH resolution: 29.9% vs 9.7% placebo (p<0.001)
- Fibrosis improvement: 25.9% vs 14.2% placebo (p<0.001)
- LDL-C reduction: -16%
- Liver fat reduction: -52% by MRI-PDFF

Safety:
- Diarrhea (27% vs 14% placebo)
- Nausea (20% vs 10% placebo)
- No liver-related serious adverse events
- Thyroid hormone levels monitored (TSH suppression expected)

Conclusion: First FDA-approved drug for NASH (March 2024). Addresses significant unmet need in a disease affecting 6-8 million Americans with fibrotic NASH. Commercial launch ongoing.

